Sotigalimab Plus Pembrolizumab Demonstrates Favorable Safety Profile in Metastatic Melanoma

Source: Cancer Network, April 2022

The combination of sotigalimab plus pembrolizumab was associated with a tolerable safety profile in patients with unresectable stage III or IV metastatic melanoma.

Patients with stage III or IV unresectable metastatic melanoma who were treated with sotigalimab plus pembrolizumab (Keytruda) demonstrated tolerable safety and immunologic changes that were associated with clinical response in a phase 1/2 dose-escalation and dose-expansion trial, according to data presented at the American Association for Cancer Research (AACR) 2022 Annual Meeting.

Investigators identified broad immune activity with the CD40 agonist antibody in both local and distant lesions through biomarker analysis.

READ THE ORIGINAL FULL ARTICLE
Menu